Atrial fibrillation
AF catheter ablation: indications
Gives the class of recommendation for catheter ablation of atrial fibrillation from the AF pattern (paroxysmal, persistent, long-standing persistent), symptoms (with the modified EHRA symptom class, mEHRA 1–4) and antiarrhythmic drug history, as first-line therapy or after drugs have failed. It covers heart failure (HFrEF with or without suspected AF-mediated cardiomyopathy, HFpEF, end-stage HF), tachy-brady syndrome, repeat and hybrid ablation, and concomitant surgical ablation. The ESC 2024 guideline, the ACC/AHA/ACCP/HRS 2023 guideline and the EHRA/HRS/APHRS/LAHRS 2024 consensus are shown side by side, followed by peri-procedural anticoagulation and risk factor management.
Upload a report, lab sheet or echo picture to fill this calculator automatically.
AF pattern
Use the main pattern of the last 6 months
Symptoms attributable to AF
mEHRA symptom class (optional)
Rate symptoms while in AF: palpitations, fatigue, dizziness, dyspnoea, chest pain, anxiety. Picking a class sets the choice above.
Antiarrhythmic drugs (class I or III)
Heart failure
ESC 2026: HFrEF < 50%, HFpEF ≥ 50%
Cardiac surgery planned
AF catheter ablation
Ablation indicated
Strongest class: I
Indications
ESC
- Catheter ablation is recommended as a first-line optionIParoxysmal AF, within shared decision-making on rhythm control, to reduce symptoms, recurrence and progression (EARLY-AF, STOP AF First, Cryo-FIRST).
ACC/AHA/ACCP/HRS 2023
- Catheter ablation as first-line therapy can be useful2aSymptomatic paroxysmal AF managed with rhythm control, in patients other than the younger ones with few comorbidities.
EHRA/HRS/APHRS/LAHRS 2024 consensus
- Catheter ablation is recommended as first-line therapyISymptomatic paroxysmal AF.
Around the procedure
- Pulmonary vein isolation is the procedural endpointIESC · EHRAExtra lesions beyond PVI (posterior wall, lines, CFAE) have no proven benefit as a routine and are IIb at most.
- Anticoagulate for ≥ 3 weeks before, or image the LA appendageIEHRAESC 2024 gives this IIa for patients at raised thromboembolic risk. Use a TOE or ICE before the procedure when anticoagulation is short or uncertain.
- Do the procedure without interrupting OACIESC · ACC · EHRAHolding one morning DOAC dose is acceptable (EHRA).
- Continue OAC for ≥ 2 months after ablation (ACC/AHA: ≥ 3 months)IESC · EHRAAfter that, base long-term OAC on CHA₂DS₂-VA, not on whether the ablation worked.
- Manage risk factors before and after ablationIESC · ACC · EHRAWeight loss, BP, alcohol, OSA, diabetes, physical activity (LEGACY, ARREST-AF). These improve the success rate.
References
- Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2024;45:3314-3414.
- Joglar JA, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the diagnosis and management of atrial fibrillation. Circulation 2024;149:e1-e156.
- Tzeis S, et al. 2024 EHRA/HRS/APHRS/LAHRS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2024;26:euae043.
- Andrade JG, et al. Cryoablation or drug therapy for initial treatment of atrial fibrillation (EARLY-AF). N Engl J Med 2021;384:305-315.
- Wazni OM, et al. Cryoballoon ablation as initial therapy for atrial fibrillation (STOP AF First). N Engl J Med 2021;384:316-324.
- Marrouche NF, et al. Catheter ablation for atrial fibrillation with heart failure (CASTLE-AF). N Engl J Med 2018;378:417-427.
- Sohns C, et al. Catheter ablation in end-stage heart failure with atrial fibrillation (CASTLE-HTx). N Engl J Med 2023;389:1380-1389.
- Packer DL, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation (CABANA). JAMA 2019;321:1261-1274.
- Wynn GJ, et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace 2014;16:965-972.
- DeLurgio DB, et al. Hybrid convergent procedure for the treatment of persistent and long-standing persistent atrial fibrillation (CONVERGE). Circ Arrhythm Electrophysiol 2020;13:e009288.